Delivery Order 36F79720D0099-36C24525N0988
Award Date
9/12/25
Potential Completion Date
9/17/25
Potential Value
$13K
Federal Agency
Veterans Integrated Service Network 5
Ultimate Awardee
Not listed
NAICS Category
325412 - Pharmaceutical Preparation Manufacturing
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Pittsburgh, PA 15275, USA
Solicitation Procedures
Multiple Award, Fair Opportunity
Number Of Offers Received
1
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award was issued by the Department of Veterans Affairs (VA) to Otsuka America Pharmaceutical Inc., a for-profit pharmaceutical manufacturer and supplier. The contract, valued at $12,559.90, is for the delivery of the drug JYNARQUE (tolvaptan) in 90mg-30mg dosages. JYNARQUE is used to treat autosomal dominant polycystic kidney disease and hyponatremia. The contract is a Delivery Order under Otsuka's existing Federal Supply Schedule (FSS) contract with the VA, which has a...
This federal contract award was made by the U.S. Department of Veterans Affairs (VA) to Otsuka America Pharmaceutical Inc., a for-profit pharmaceutical manufacturer and supplier. The award, valued at $12,559.90, is for the delivery of the drug Jynarque (tolvaptan) in 90mg/30mg dosage to VA medical facilities and integrated service networks. Jynarque is used to treat autosomal dominant polycystic kidney disease and hyponatremia. The contract is a Delivery Order issued under Otsuka's existing...
This federal contract award was made by the Department of Veterans Affairs (VA) to Otsuka America Pharmaceutical Inc., a for-profit pharmaceutical manufacturer based in Rockville, Maryland. The $13,168.39 firm-fixed-price delivery order is for the drug JYNARQUE (tolvaptan), which is used to treat autosomal dominant polycystic kidney disease and hyponatremia. The contract is issued under the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB) and does not utilize any set-aside...
This federal contract award is for the drug JYNARQUE, which is used to treat autosomal dominant polycystic kidney disease and hyponatremia. The $100,645.76 firm-fixed price delivery order was awarded to Otsuka America Pharmaceutical Inc., a for-profit pharmaceutical manufacturer, by the U.S. Department of Veterans Affairs (VA) under the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB). The contract has an ultimate completion date of March 25, 2024. Otsuka holds two significant...
This is a firm-fixed price delivery order contract awarded by the Department of Veterans Affairs (VA) to Otsuka America Pharmaceutical Inc., a for-profit pharmaceutical manufacturer and supplier. The contract, valued at $730,030.82, is for the delivery of the drug Jynarque (tolvaptan) to VA medical facilities across the country. Jynarque is used to treat autosomal dominant polycystic kidney disease and hyponatremia. The contract is issued under the VA's Pharmaceuticals and Drugs Federal Supply...
This federal contract award is to Otsuka America Pharmaceutical Inc., a for-profit pharmaceutical manufacturer and supplier, to provide the drug Jynarque (tolvaptan) to the Department of Veterans Affairs (VA) Veterans Health Administration (VHA). The $73,251.35 firm-fixed price delivery order falls under Otsuka's $396 million Federal Supply Schedule (FSS) contract for Pharmaceuticals and Drugs (FSS-61-IB), which enables Otsuka to deliver medications to VA facilities nationwide through March...
This federal contract award was made by the Department of Veterans Affairs (VA) to Otsuka America Pharmaceutical Inc., a for-profit pharmaceutical manufacturer and supplier. The contract is for the delivery of the medication Jynarque (tolvaptan), which is used to treat autosomal dominant polycystic kidney disease and hyponatremia. The contract is a Blanket Purchase Agreement (BPA) with a ceiling value of $113,303.91 and a period of performance from October 2020 to October 2021. It was awarded...
This federal contract award was issued by the Department of Veterans Affairs (VA) to Otsuka America Pharmaceutical Inc., a for-profit pharmaceutical manufacturer and supplier. The contract is a Delivery Order against Otsuka's $396 million Federal Supply Schedule (FSS-61-IB) for Pharmaceuticals and Drugs, which allows the VA to procure a range of Otsuka's commercial drug offerings. The primary product being delivered under this $12,580.72 firm-fixed price contract is Jynarque (tolvaptan), a...
This federal contract award was issued by the Veterans Integrated Service Network 21 (VISN 21), a civilian agency under the Department of Veterans Affairs (VA), to Otsuka America Pharmaceutical Inc., a for-profit pharmaceutical manufacturer. The contract is a delivery order with a ceiling value of $12,580.72 for the drug Jynarque (tolvaptan) 45mg/15mg. Jynarque is used to treat autosomal dominant polycystic kidney disease and hyponatremia. This award is associated with a larger Blanket...
This federal contract award is for the delivery of the drug Jynarque (tolvaptan) to the Department of Veterans Affairs (VA) Veterans Health Administration (VHA) facilities and VA Veterans Integrated Service Networks. The contract was awarded to the prime contractor Otsuka America Pharmaceutical Inc., a for-profit manufacturer and supplier of pharmaceuticals. The contract has a potential value of $146,493.98 and was awarded on a firm-fixed price basis with no set-aside designation. It is...